Seqirus announced today that the US Food and Drug Administration (FDA) has approved Fluad Quadrivalent, touted as the first and only adjuvanted quadrivalent influenza vaccine, developed to help protect adults 65 years and older against seasonal influenza.
“These estimates are reassuring,” says Brendan Flannery, PhD, the CDC’s investigator for the US Flu Vaccine Effectiveness Network.
Health officials say that this is a particularly bad year for an extended influenza season since flu symptoms and some of the symptoms of the novel coronavirus, COVID-19, are the same (fever, cough, shortness of breath).
An adjuvanted influenza A H5N1 monovalent vaccine (Audenz) has been approved by the US Food and Drug Administration (FDA). The approval was granted to Seqirus.
Rebecca Leach, RN, BSN, MPH, CIC, speaks to Infection Control Today about dealing with respiratory illnesses during the flu season.